Atour (ATAT.US) Preview: Expecting Weak 4Q22 and Strong 2023
Although the operating metrics are expected to be weak in 4Q22 due to the lingering of Covid effects, we expect the resumption of travel to...
422 Views
Atour(ATAT.US) Initiation: Buy for First-Stage Single-Brand Network Expansion
We expect Atourās network to expand to 2,500+ in 2025 from the current 900+. We initiate Atour (ATAT US) with a BUY rating and target price of...
563 Views
Atour Lifestyle Holdings IPO Analysis
Atour Lifestyle Holdings (ATAT US) is a leading upper midscale hotel chain group in China is getting ready for an IPO in the US. We provide an in...
410 Views
ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
684 Views
ECM Weekly (27th June 2021) - Didi, Xpeng, Zylox, Dingdong, EBeauty, Chaoju Eye Care, Keymed Bio
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
598 Views